286 related articles for article (PubMed ID: 17702867)
1. Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice.
Rommelfanger KS; Edwards GL; Freeman KG; Liles LC; Miller GW; Weinshenker D
Proc Natl Acad Sci U S A; 2007 Aug; 104(34):13804-9. PubMed ID: 17702867
[TBL] [Abstract][Full Text] [Related]
2. Differential interactive effects of gliotoxin and MPTP in the substantia nigra and the locus coeruleus in BALB/c mice.
Chang FW; Wang SD; Lu KT; Lee EH
Brain Res Bull; 1993; 31(3-4):253-66. PubMed ID: 7683960
[TBL] [Abstract][Full Text] [Related]
3. Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the substantia nigra and the locus coeruleus in BALB/c mice.
Hu SC; Chang FW; Sung YJ; Hsu WM; Lee EH
J Pharmacol Exp Ther; 1991 Dec; 259(3):1379-87. PubMed ID: 1684822
[TBL] [Abstract][Full Text] [Related]
4. Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.
Leng A; Mura A; Hengerer B; Feldon J; Ferger B
Behav Brain Res; 2004 Oct; 154(2):375-83. PubMed ID: 15313025
[TBL] [Abstract][Full Text] [Related]
5. Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement.
Espay AJ; LeWitt PA; Kaufmann H
Mov Disord; 2014 Dec; 29(14):1710-9. PubMed ID: 25297066
[TBL] [Abstract][Full Text] [Related]
6. alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach.
Bazzu G; Calia G; Puggioni G; Spissu Y; Rocchitta G; Debetto P; Grigoletto J; Zusso M; Migheli R; Serra PA; Desole MS; Miele E
CNS Neurol Disord Drug Targets; 2010 Aug; 9(4):482-90. PubMed ID: 20522009
[TBL] [Abstract][Full Text] [Related]
7. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
8. Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletions.
Fornai F; Alessandrì MG; Torracca MT; Bassi L; Corsini GU
J Pharmacol Exp Ther; 1997 Oct; 283(1):100-7. PubMed ID: 9336313
[TBL] [Abstract][Full Text] [Related]
9. MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity.
Thomas B; von Coelln R; Mandir AS; Trinkaus DB; Farah MH; Leong Lim K; Calingasan NY; Flint Beal M; Dawson VL; Dawson TM
Neurobiol Dis; 2007 May; 26(2):312-22. PubMed ID: 17336077
[TBL] [Abstract][Full Text] [Related]
10. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
Sconce MD; Churchill MJ; Greene RE; Meshul CK
Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481
[TBL] [Abstract][Full Text] [Related]
11. Protective role of SIRT5 against motor deficit and dopaminergic degeneration in MPTP-induced mice model of Parkinson's disease.
Liu L; Peritore C; Ginsberg J; Shih J; Arun S; Donmez G
Behav Brain Res; 2015 Mar; 281():215-21. PubMed ID: 25541039
[TBL] [Abstract][Full Text] [Related]
12. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
[TBL] [Abstract][Full Text] [Related]
13. Aging of the dopaminergic system and motor behavior in mice intoxicated with the parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Schumm S; Sebban C; Cohen-Salmon C; Callebert J; Launay JM; Golmard JL; Boussicault L; Petropoulos I; Hild A; Rousselet E; Prigent A; Friguet B; Mariani J; Hirsch EC
J Neurochem; 2012 Sep; 122(5):1032-46. PubMed ID: 22708926
[TBL] [Abstract][Full Text] [Related]
14. Destruction of norepinephrine terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice reduces locomotor activity induced by L-dopa.
Nishi K; Kondo T; Narabayashi H
Neurosci Lett; 1991 Feb; 123(2):244-7. PubMed ID: 2027538
[TBL] [Abstract][Full Text] [Related]
15. Intervention with 7,8-dihydroxyflavone blocks further striatal terminal loss and restores motor deficits in a progressive mouse model of Parkinson's disease.
Sconce MD; Churchill MJ; Moore C; Meshul CK
Neuroscience; 2015 Apr; 290():454-71. PubMed ID: 25655214
[TBL] [Abstract][Full Text] [Related]
16. Comparative studies of the neurotoxicity of MPTP in rats of different ages.
Lee EH; Liu SP; Lu KT; Lin WR
Chin J Physiol; 1992; 35(4):317-36. PubMed ID: 1364057
[TBL] [Abstract][Full Text] [Related]
17. Behavioral responses of dopamine beta-hydroxylase knockout mice to modafinil suggest a dual noradrenergic-dopaminergic mechanism of action.
Mitchell HA; Bogenpohl JW; Liles LC; Epstein MP; Bozyczko-Coyne D; Williams M; Weinshenker D
Pharmacol Biochem Behav; 2008 Dec; 91(2):217-22. PubMed ID: 18703079
[TBL] [Abstract][Full Text] [Related]
18. Neuronal and astroglial responses to the serotonin and norepinephrine neurotoxin: 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine.
Luellen BA; Miller DB; Chisnell AC; Murphy DL; O'Callaghan JP; Andrews AM
J Pharmacol Exp Ther; 2003 Dec; 307(3):923-31. PubMed ID: 14561848
[TBL] [Abstract][Full Text] [Related]
19. Pain perception in acute model mice of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Park J; Lim CS; Seo H; Park CA; Zhuo M; Kaang BK; Lee K
Mol Pain; 2015 May; 11():28. PubMed ID: 25981600
[TBL] [Abstract][Full Text] [Related]
20. Nei-like 1 inhibition results in motor dysfunction and promotes inflammation in Parkinson's disease mice model.
Xue B; Xiao W; Tian H
Biochem Biophys Res Commun; 2020 Jan; 521(1):245-251. PubMed ID: 31653343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
